Breast Cancer Survivorship Biorepository
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- University of Southern California
- Study ID
- NCT05786664
- Status
- Recruiting
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Invasive Breast Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Biospecimen Collection — PROCEDUREUndergo collection of blood samples
- Electronic Health Record Review — OTHERReview of records
- Quality-of-Life Assessment — OTHERComplete quality-of-life questionnaires
- Survey Administration — OTHERComplete surveys
Study Details
This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.
Key Dates
- Start date
- Apr 11, 2022
- Status verified
- May 2026
- Primary completion
- Apr 11, 2027
- Completion
- Apr 11, 2028
Study Design
- Enrollment
- 1,300 participants (estimated)
Arms
- Arm: Observational (survey, biospecimen collection, record review)Patients complete surveys, undergo collection of blood samples, and review of medical records on study.
Primary Outcome Measure
Biorepository [ Time Frame: 5 years ]
Central Contacts
- Audrey Saghian, MPH323-865-6086
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Bodour Salhia, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
By research site
Related Studies
- Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast CancerRecruiting · M.D. Anderson Cancer Center · Gilbert, Arizona
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Orange, California
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationRecruiting · Guardant Health, Inc. · Birmingham, Alabama
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruiting · Alliance for Clinical Trials in Oncology · Anchorage, Alaska